

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**VOLUNTARY ANNOUNCEMENT
FRAMEWORK AGREEMENT FOR ACQUISITION OF CONCESSION
RIGHTS**

This announcement is made by Zhong Ji Longevity Science Group Limited (the “**Company**”) on a voluntary basis.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that on 13 July 2021, the Company entered into a framework agreement for the acquisition of concession rights (the “**Framework Agreement**”) with East Rise Medical Channel Limited (“**East Rise Medical**”), pursuant to which the Company shall, subject to the outcome of the Independent Valuation, exclusively acquire the wholesale rights of vaccines and antibiotics as well as the wholesale rights of western pharmaceuticals owned by East Rise Medical (the “**Potential Acquisition**”).

Both parties agreed to appoint an independent valuer to conduct a professional assessment on the commercial value of the operating permits for antibiotics and vaccines as well as the pharmaceutical wholesale dealer license owned by East Rise Medical (the “**Independent Valuation**”), plus the time cost of the application. The Company shall make a reasonably priced offer to East Rise Medical with reference to the valuation report, so that the Company can immediately obtain the legal rights to operate vaccines and antibiotics, and lay the foundation for large-scale purchases and sales in the international market, which will enable the Company to make its due contribution to international prevention and control efforts in the face of the COVID-19 pandemic.

Upon completion of the Potential Acquisition, the Company will form and integrate its existing biologics marketing and management team to establish a global sales network for vaccines, antibiotics and long-life biologics, particularly in the Greater China region.

INFORMATION ON EAST RISE MEDICAL

East Rise Medical is a pharmaceutical wholesale company established in 2016 with worldwide business presence. It has a wholesale dealer license under the Pharmacy and Poisons Ordinance (Cap. 138) and a license to deal in substances and preparations to which the Antibiotics Ordinance (Cap. 137) applies, and has the advantage of being licensed to operate vaccines legally.

REASONS FOR AND BENEFITS OF THE FRAMEWORK AGREEMENT

The Board believes that the Potential Acquisition will further improve the Group's global footprint in longevity science, and further enhance its leading position in longevity medicine, which will bring stable and sustainable revenue growth to the Group in the long run.

Shareholders and potential investors of the Company are reminded that the Potential Acquisition may or may not proceed. If the transaction contemplated under the Framework Agreement materializes, a further announcement will be made by the Company in accordance with the Listing Rules in due course. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman

Hong Kong, 13 July 2021

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (Chairman)
Mr. Wang Hongxin (*Chief Executive Officer*)
Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Tam Ho Leung Simon
Ms. Wang Weixia
Mr. Chai Nan

Non-executive Director

Ms. Choi Ngai Wah

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.